Thematic review series: Adipocyte Biology - Lipodystrophies: Windows on adipose biology and metabolism

Journal of Lipid Research

Volumn 48, Issue 7, 2007, Pages 1433-1444

  Hegele, Robert A ^a   Joy, Tisha R ^a   Al Attar, Salam A ^a   Rutt, Brian K ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Dyslipidemia; Fatty acid; Genetics; Insulin resistance; Laminopathy; Medical imaging; Metabolism; Nuclear hormone receptors; Obesity; Type 2 diabetes

Indexed keywords

1 ACYLGLYCEROL 3 PHOSPHATE O ACYLTRANSFERASE 2; ACYLTRANSFERASE; ENZYME ZMPSTE24; LAMIN; LAMIN A; LAMIN B2; MEMBRANE PROTEIN; METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SEIPIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BARRAQUER SIMONS ACQUIRED PARTIAL LIPODYSTROPHY; BERARDINELLI SEIP CONGENITAL GENERALIZED LIPODYSTROPHY TYPE 1; BERARDINELLI SEIP CONGENITAL GENERALIZED LIPODYSTROPHY TYPE 2; DUNNIGAN TYPE FAMILIAL PARTIAL LIPODYSTROPHY TYPE 2; GENE MUTATION; GROWTH DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS RELATED LIPODYSTROPHY; IMAGING SYSTEM; LIPID METABOLISM; LIPODYSTROPHY; PARTIAL DYSTROPHY WITH MANDIBULOACRAL DYSPLASIA TYPE A; PARTIAL DYSTROPHY WITH MANDIBULOACRAL DYSPLASIA TYPE B; PATHOGENESIS; PRIORITY JOURNAL; PROGERIA SYNDROME; REVIEW; SHORT SYNDROME; WERNER SYNDROME; WIEDEMANN RAUTENSTRAUCH NEONATAL PROGEROID SYNDROME;

ADIPOSE TISSUE; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPODYSTROPHY; LIPODYSTROPHY, CONGENITAL GENERALIZED; LIPODYSTROPHY, FAMILIAL PARTIAL; MAGNETIC RESONANCE IMAGING;

EID: 34548148047     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R700004-JLR200     Document Type: Review

References (89)

1. Garg, A. 2004. Acquired and inherited lipodystrophies. N. Engl. J. Med. 350: 1220-1234.
2. Simha, V., and A. Garg. 2006. Lipodystrophy: lessons in lipid and energy metabolism. Curr. Opin. Lipidol. 17: 162-169.
3. Hegele, R. A. 2003. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol. Metab. 14: 371-377.
4. Hegele, R. A. 2004. Phenomics, lipodystrophy, and the metabolic syndrome. Trends Cardiovasc. Med. 14: 133-137.
5. Berardinelli, W. 1954. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J. Clin. Endocrinol. Metab. 14: 193-204.
6. Seip, M. 1959. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta Paediatr. 48: 555-574.
7. Seip, M., and O. Trygstad. 1996. Generalized lipodystrophy, congenital and acquired (lipoatrophy). Acta Paediatr. Suppl. 413: 2-28.
8. Westvik, J. 1996. Radiological features in generalized lipodystrophy. Acta Paediatr. Suppl. 413: 44-51.
9. Fleckenstein, J. L., A. Garg, F. J. Bonte, M. F. Vuitch, and R. M. Peshock. 1992. The skeleton in congenital, generalized lipodystrophy: evaluation using whole-body radiographic surveys, magnetic resonance imaging and technetium-99m bone scintigraphy. Skeletal Radiol. 21: 381-386.
10. Agarwal, A. K., V. Simha, E. A. Oral, S. A. Moran, P. Gorden, S. O'Rahilly, Z. Zaidi, F. Gurakan, S. A. Arslanian, A. Klar, et al. 2003. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J. Clin. Endocrinol. Metab. 88: 4840-4847.
11. Bhayana, S., V. M. Siu, G. I. Joubert, C. L. Clarson, H. Cao, and R. A. Hegele. 2002. Cardiomyopathy in congenital complete lipodystrophy. Clin. Genet. 61: 283-287.
12. Haque, W. A., I. Shimomura, Y. Matsuzawa, and A. Garg. 2002. Serum adiponectin and leptin levels in patients with lipodystrophies. J. Clin. Endocrinol. Metab. 87: 2395-2998.
13. Agarwal, A. K., and A. Garg. 2006. Genetic basis of lipodystrophies and management of metabolic complications. Annu. Rev. Med. 57: 297-311.
14. Garg, A., R. Wilson, R. Barnes, E. Arioglu, Z. Zaidi, F. Gurakan, N. Kocak, S. O'Rahilly, S. I. Taylor, S. B. Patel, et al. 1999. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J. Clin. Endocrinol. Metab. 84: 3390-3394.
15. Agarwal, A. K., E. Arioglu, S. De Almeida, N. Akkoc, S. I. Taylor, A. M. Bowcock, R. I. Barnes, and A. Garg. 2002. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. 31: 21-23.
16. Agarwal, A. K., and A. Garg. 2003. Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends Endocrinol. Metab. 14: 214-221.
17. Vergnes, L., A. P. Beigneux, R. Davis, S. M. Watkins, S. G. Young, and K. Reue. 2006. Agpat6 deficiency causes subdermal lipodystrophy and resistance to obesity. J. Lipid Res. 47: 745-754.
18. Magre, J., M. Delepine, E. Khallouf, T. Gedde-Dahl, Jr., L. Van Maldergem, E. Sobel, J. Papp, M. Meier, A. Megarbane, A. Bachy, et al. 2001. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat. Genet. 28: 365-370.
19. Lundin, C., R. Nordstrom, K. Wagner, C. Windpassinger, H. Andersson, G. von Heijne, and I. Nilsson. 2006. Membrane topology of the human seipin protein. FEBS Lett. 580: 2281-2284.
20. Windpassinger, C., M. Auer-Grumbach, J. Irobi, H. Patel, E. Petek, G. Horl, R. Malli, J. A. Reed, I. Dierick, N. Verpoorten, et al. 2004. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat. Genet. 36: 271-276.
21. Van Maldergem, L., J. Magre, T. E. Khallouf, T. Gedde-Dahl, Jr., M. Delepine, O. Trygstad, E. Seemanova, T. Stephenson, C. S. Albott, F. Bonnici, et al. 2002. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J. Med. Genet. 39: 722-733.
22. Fu, M., R. Kazlauskaite, F. Baracho Mde, M. G. Santos, J. Brandao-Neto, S. Villares, F. S. Celi, B. L. Wajchenberg, and A. R. Shuldiner. 2004. Mutations in Gng3lg and AGPAT2 in Berardinelli-Seip congenital lipodystrophy and Brunzell syndrome: phenotype variability suggests important modifier effects. J. Clin. Endocrinol. Metab. 89: 2916-2922.
23. Brunzell, J. D., S. W. Shankle, and J. E. Bethune. 1968. Congenital generalized lipodystrophy accompanied by cystic angiomatosis. Ann. Intern. Med. 69: 501-516.
24. Gomes, K. B., V. C. Pardini, A. C. Ferreira, and A. P. Fernandes. 2005. Phenotypic heterogeneity in biochemical parameters correlates with mutations in AGPAT2 or Seipin genes among Berardinelli-Seip congenital lipodystrophy patients. J. Inherit. Metab. Dis. 28: 1123-1131.
25. Simha, V., and A. Garg. 2003. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J. Clin. Endocrinol. Metab. 88: 5433-5437.
26. Kobberling, J., B. Willms, R. Kattermann, and W. Creutzfeldt. 1975. Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetes. Humangenetik. 29: 111-120.
27. Dunnigan, M. G., M. A. Cochrane, A. Kelly, and J. W. Scott. 1974. Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q. J. Med. 43: 33-48.
28. Kobberling, J., and M. G. Dunnigan. 1986. Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state. J. Med. Genet. 23: 120-127.
29. Garg, A., R. M. Peshock, and J. L. Fleckenstein. 1999. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab. 84: 170-174.
30. Garg, A., M. Vinaitheerthan, P. T. Weatherall, and A. M. Bowcock. 2001. Phenotypic heterogeneity in patients with familial partial lipodystrophy (Dunnigan variety) related to the site of missense mutations in lamin A/C gene. J. Clin. Endocrinol. Metab. 86: 59-65.
31. Hegele, R. A. 2005. Lessons from human mutations in PPAR-gamma. Int. J. Obes. (Lond). 29 (Suppl. 1): 31-35.
32. Ludtke, A., J. Genschel, G. Brabant, J. Bauditz, M. Taupitz, M. Koch, W. Wermke, H. J. Worman, and H. H. Schmidt. 2005. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am. J. Gastroenterol. 100: 2218-2224.
33. Garg, A. 2000. Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J. Clin. Endocrinol. Metab. 85: 1776-1782.
34. Haque, W. A., E. A. Oral, K. Dietz, A. M. Bowcock, A. K. Agarwal, and A. Garg. 2003. Risk factors for diabetes in familial partial lipodystrophy, Dunnigan variety. Diabetes Care. 26: 1350-1355.
35. Cao, H., and R. A. Hegele. 2000. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 9: 109-112.
36. Herbst, K. L., L. R. Tannock, S. S. Deeb, J. Q. Purnell, J. D. Brunzell, and A. Chait. 2003. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care. 26: 1819-1824.
37. Hegele, R. 2005. LMNA mutation position predicts organ system involvement in laminopathies. Clin. Genet. 68: 31-34.
38. Capell, B. C., and F. S. Collins. 2006. Human laminopathies: nuclei gone genetically awry. Nat. Rev. Genet. 7: 940-952.
39. Young, S. G., M. Meta, S. H. Yang, and L. G. Fong. 2006. Prelamin A farnesylation and progeroid syndromes. J. Biol. Chem. 281: 39741-39745.
40. Fong, L. G., D. Frost, M. Meta, X. Qiao, S. H. Yang, C. Coffinier, and S. G. Young. 2006. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science. 311: 1621-1623.
41. Lanktree, M., H. Cao, S. Rabkin, A. Hanna, and R. Hegele. 2007. Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660). Clin. Genet. 71: 183-186.
42. Hegele, R. A., H. Cao, D. M. Liu, G. A. Costain, V. Charlton-Menys, N. W. Rodger, and P. N. Durrington. 2006. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am. J. Hum. Genet. 79: 383-389.
43. Agarwal, A. K., and A. Garg. 2002. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 87: 408-411.
44. Agostini, M., E. Schoenmakers, C. Mitchell, I. Szatmari, D. Savage, A. Smith, O. Rajanayagam, R. Semple, J. Luan, L. Bath, et al. 2006. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab. 4: 303-311.
45. Al-Shali, K., H. Cao, N. Knoers, A. R. Hermus, C. J. Tack, and R. A. Hegele. 2004. A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy. J. Clin. Endocrinol. Metab. 89: 5655-5660.
46. Francis, G. A., G. Li, R. Casey, J. Wang, H. Cao, T. Leff, and R. A. Hegele. 2006. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet. 7: 3.
47. Hegele, R. A., H. Cao, C. Frankowski, S. T. Mathews, and T. Leff. 2002. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 51: 3586-3590.
48. Hegele, R. A., E. Ur, T. P. Ransom, and H. Cao. 2006. A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clin. Genet. 70: 360-362.
49. Li, G., and T. Leff. 2007. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-{gamma} mutations associated with diabetes. Mol. Endocrinol. 21: 857-864.
50. Monajemi, H., L. Zhang, G. Li, E. H. Jeninga, H. Cao, M. Maas, C. B. Brouwer, E. Kalkhoven, E. Stroes, R. A. Hegele, et al. 2007. Familial partial lipodystrophy phenotype resulting from a single-base mutation in DNA binding domain of peroxisome proliferator-activated receptor gamma. J. Clin. Endocrinol. Metab. 92: 1606-1612.
51. Savage, D. B., G. D. Tan, C. L. Acerini, S. A. Jebb, M. Agostini, M. Gurnell, R. L. Williams, A. M. Umpleby, E. L. Thomas, J. D. Bell, et al. 2003. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 52: 910-917.
52. Morel, C. F., M. A. Thomas, H. Cao, C. H. O'Neil, J. G. Pickering, W. D. Foulkes, and R. A. Hegele. 2006. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2. J. Clin. Endocrinol. Metab. 91: 2689-2695.
53. Hegele, R. A., H. Cao, C. M. Anderson, and I. M. Hramiak. 2000. Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy. J. Clin. Endocrinol. Metab. 85: 3431-3435.
54. Hegele, R. A. 2001. Premature atherosclerosis associated with monogenic insulin resistance. Circulation. 103: 2225-2229.
55. Barraquer, L. 1907. Histoire clinique d'un cas d'atrophie du tissue celluloadipeux. Neurolog. Zentralblatt. 26: 1072-1080.
56. Mitchell, S. W. 1885. Singular case of absence of adipose tissue matter in the upper half of the body. Am. J. Med. Sci. 90: 105-106.
57. Simons, A. 1911. Lipodystrophia progressive. Z. Ges. Neurol. Psychiat. 5: 29-38.
58. Misra, A., A. Peethambaram, and A. Garg. 2004. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 83: 18-34.
59. Hegele, R. A., J. Yuen, and H. Cao. 2001. Single-nucleotide polymorphisms of the nuclear lamina proteome. J. Hum. Genet. 46: 351-354.
60. Frey, B. J., N. Mohammad, Q. D. Morris, W. Zhang, M. D. Robinson, S. Mnaimneh, R. Chang, Q. Pan, E. Sat, J. Rossant, et al. 2005. Genome-wide analysis of mouse transcripts using exon microarrays and factor graphs. Nat. Genet. 37: 991-996.
61. Misra, A., and A. Garg. 2003. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine (Baltimore). 82: 129-146.
62. Chen, D., A. Misra, and A. Garg. 2002. Clinical review 153. Lipodystrophy in human immunodeficiency virus-infected patients. J. Clin. Endocrinol. Metab. 87: 4845-4856.
63. Lo, J. C., K. Mulligan, V. W. Tai, H. Algren, and M. Schambelan. 1998. "Buffalo hump" in men with HIV-1 infection. Lancet. 351: 867-870.
64. Miller, K. K., P. A. Daly, D. Sentochnik, J. Doweiko, M. Samore, N. O. Basgoz, and S. K. Grinspoon. 1998. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 27: 68-72.
65. Roth, V. R., S. Kravcik, and J. B. Angel. 1998. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin. Infect. Dis. 27: 65-67.
66. F. R. A. M. Investigators. 2006. Fat distribution in women with HIV infection. J. Acquir. Immune Defic. Syndr. 42: 562-571.
67. Bacchetti, P., B. Gripshover, C. Grunfeld, S. Heymsfield, H. McCreath, D. Osmond, M. Saag, R. Scherzer, M. Shlipak, and P. Tien. 2005. Fat distribution in men with HIV infection. J. Acquir. Immune Defic. Syndr. 40: 121-131.
68. Tien, P. C., S. R. Cole, C. M. Williams, R. Li, J. E. Justman, M. H. Cohen, M. Young, N. Rubin, M. Augenbraun, and C. Grunfeld. 2003. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J. Acquir. Immune Defic. Syndr. 34: 461-466.
69. Grinspoon, S. 2005. Androgen deficiency and HIV infection. Clin. Infect. Dis. 41: 1804-1805.
70. Grinspoon, S., and A. Carr. 2005. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352: 48-62.
71. Ristig, M., H. Drechsler, and W. G. Powderly. 2005. Hepatic steatosis and HIV infection. AIDS Patient Care STDS. 19: 356-365.
72. Johnsen, S., S. E. Dolan, K. V. Fitch, K. M. Killilea, J. L. Shifren, and S. K. Grinspoon. 2005. Absence of polycystic ovary syndrome features in human immunodeficiency virus-infected women despite significant hyperinsulinemia and truncal adiposity. J. Clin. Endocrinol. Metab. 90: 5596-5604.
73. Kosmiski, L., D. Kuritzkes, K. Lichtenstein, and R. Eckel. 2003. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir. Ther. 8: 9-15.
74. Mynarcik, D. C., T. Combs, M. A. McNurlan, P. E. Scherer, E. Komaroff, and M. C. Gelato. 2002. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J. Acquir. Immune Defic. Syndr. 31: 514-520.
75. Cutler, D. L., S. Kaufmann, and G. R. Freidenberg. 1991. Insulin-resistant diabetes mellitus and hypermetabolism in mandibuloacral dysplasia: a newly recognized form of partial lipodystrophy. J. Clin. Endocrinol. Metab. 73: 1056-1061.
76. Simha, V., and A. Garg. 2002. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J. Clin. Endocrinol. Metab. 87: 776-785.
77. Novelli, G., A. Muchir, F. Sangiuolo, A. Helbling-Leclerc, M. R. D'Apice, C. Massart, F. Capon, P. Sbraccia, M. Federici, R. Lauro, et al. 2002. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am. J. Hum. Genet. 71: 426-431.
78. Bergo, M. O., B. Gavino, J. Ross, W. K. Schmidt, C. Hong, L. V. Kendall, A. Mohr, M. Meta, H. Genant, Y. Jiang, et al. 2002. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. USA. 99: 13049-13054.
79. Aarskog, D., L. Ose, H. Pande, and N. Eide. 1983. Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes. Am. J. Med. Genet. 15: 29-38.
80. Gorlin, R. J., J. Cervinka, K. Moller, M. Horrobin, and J. Witkop. 1975. Rieger anomaly and growth retardation (the S-H-O-R-T syndrome). Birth Defects Orig. Artic. Ser. 11: 46-48.
81. Sorge, G., M. Ruggieri, A. Polizzi, A. Scuderi, and M. Di Pietro. 1996. SHORT syndrome: a new case with probable autosomal dominant inheritance. Am. J. Med. Genet. 61: 178-181.
82. Hennekam, R. C. 2006. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am. J. Med. Genet. A. 140: 2603-2624.
83. Pollex, R. L., and R. A. Hegele. 2004. Hutchinson-Gilford progeria syndrome. Clin. Genet. 66: 375-381.
84. Navarro, C. L., P. Cau, and N. Levy. 2006. Molecular bases of progeroid syndromes. Hum. Mol. Genet. 15 (Spec. 2): R151-R161.
85. Hoepffner, H. J., M. Dreyer, U. Reimers, U. Schmidt-Preuss, H. P. Koepp, and H. W. Rudiger. 1989. A new familial syndrome with impaired function of three related peptide growth factors. Hum. Genet. 83: 209-216.
86. Lebel, M. 2001. Werner syndrome: genetic and molecular basis of a premature aging disorder. Cell. Mol. Life Sci. 58: 857-867.
87. Pivnick, E. K., B. Angle, R. A. Kaufman, B. D. Hall, P. Pitukcheewanont, J. H. Hersh, J. L. Fowlkes, L. P. Sanders, J. M. O'Brien, G. S. Carroll, et al. 2000. Neonatal progeroid (Wiedemann-Rautenstrauch) syndrome: report of five new cases and review. Am. J. Med. Genet. 90: 131-140.
88. Al-Attar, S. A., R. L. Pollex, J. F. Robinson, B. A. Miskie, R. Walcarius, B. K. Rutt, and R. A. Hegele. 2006. Semi-automated segmentation and quantification of adipose tissue in calf and thigh by MRI: a preliminary study in patients with monogenic metabolic syndrome. BMC Med. Imaging. 6: 11.
89. Al-Attar, S. A., R. L. Pollex, J. F. Robinson, B. A. Miskie, R. Walcarius, C. H. Little, B. K. Rutt, and R. A. Hegele. 2007. Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Med. Imaging. 7: 3.